Guidance, NICE advice and quality standards in development | Guidance

Showing 1 to 10 of 389

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years ID6510	Technology appraisal guidance	TBC
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]	Technology appraisal guidance	TBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer [TSID12065]	Technology appraisal guidance	TBC
Abicipar pegol for treating wet age-related macular degeneration [ID1533]	Technology appraisal guidance	TBC
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) [ID6378]	Technology appraisal guidance	5 November 2025
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]	Technology appraisal guidance	22 April 2026
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]	Technology appraisal guidance	TBC
Acoramidis for treating transthyretin-related amyloidosis cardiomyopathy [ID6354]	Technology appraisal guidance	11 December 2025
Advanced breast cancer: diagnosis and management (Partial update)	NICE guideline	26 February 2026
Aggressive behaviour in people receiving NHS or social care: prevention and management	NICE guideline	TBC